Biologics News

Before patients undergo knee arthroscopy, synovial fluid biomarkers can reflect the intra-articular environment and potentially predict postoperative clinical outcomes, according to results.

BARCELONA, Spain — At the European Society of Sports Traumatology, Knee Surgery & Arthroscopy Congress, investigators from Belarus reported their first clinical results using a local adherent method of autologous mesenchymal stem cell transplantation to regenerate articular cartilage.

An allograft reconstruction for skeletally immature pediatric patients with malignant bone tumors may have a high rate of complications, but can effectively manage big bone defects and provide bone stock for future procedures, according to the results of a retrospective study.

Anika Therapeutics Inc. announced it has received CE mark approval for Cingal, reportedly the first and only commercially available combination viscosupplement formulated with triamcinolone hexacetonide and the company’s proprietary crosslinked sodium hyaluronate.

Anika Therapeutics Inc. announced it has received CE mark approval for Cingal, reportedly the first and only commercially available combination viscosupplement formulated with triamcinolone hexacetonide and the company’s proprietary crosslinked sodium hyaluronate.

AlloSource announced the launch of its ProChondrix Cartilage Restoration Matrix, a cellular 3-D fresh cartilage allograft.

Investigators of this retrospective study found that for patients with preoperative anemia who underwent total joint arthroplasty, treatment with tranexamic acid and packed red blood cells was significantly less expensive than treatment with either IV iron supplementation or IV erythropoietin.

Recently published results in the Journal of Shoulder and Elbow Surgery identified two single-nucleotide polymorphisms significantly associated with rotator cuff tears.

At the American Academy of Orthopaedic Surgeons Annual Meeting, Cayenne Medical Inc. announced the launch of its BioWick platform technology.

Researchers of this multicenter pivotal FDA investigational device exemption trial found the i-Factor Bone Graft manufactured by Cerapedics Inc. met all four FDA-mandated non-inferiority success criteria, and demonstrated efficacy and safety in patients who underwent single-level anterior cervical discectomy and fusion for cervical radiculopathy.